Drug Profile
Research programme: metabolic disorders therapeutics - Synageva BioPharma/BBB Therapeutics
Latest Information Update: 07 Oct 2014
Price :
$50
*
At a glance
- Originator Synageva BioPharma
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 07 Oct 2014 No development reported for Metabolic disorders in USA (Parenteral)
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
- 07 Jan 2011 Early research in Metabolic disorders in USA (Parenteral)